Endothelin Receptor

Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.

Aminaftone (Aminaftone), a derivative of 4-aminobenzoic acid, downregulates endothelin-1 (ET-1) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.

ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke.

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine (Carperitide) is a hormone containing 28 amino acids that is produced and secreted by the heart in response to cardiac injury and mechanical stretching.

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate is a bioactive peptide that plays a crucial role in the body's homeostatic mechanisms. Atrial Natriuretic Peptide (ANP) (1-28) inhibits angiotensin II)-induced endothelin-1 secretion in a dose-dependent manner.

PD-159020 is a non-selective ETA/ETB antagonist, with IC50s of 30 and 50 nM for hETA and hETB, respectively.

Atrasentan (ABT-627) is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA.

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.

BQ-788 is a selective nonpeptide endothelin type B (ETB) receptor antagonist with an IC 50 of 1.2nM. BQ-788 can specifically bind to ETB receptors, blocking the interaction between endothelin and its receptors, thereby inhibiting endothelin-mediated effects such as vasoconstriction and cell proliferation.

Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors.

Macitentan n-butyl analogue is a n-butyl analogue of Macitentan.

Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist.

IRL-1620 TFA is a potent and selective endothelin B receptor (ETB) agonist (K i =16pM).

An internal standard for the quantification of macitentan

Highly potent, selective ETA antagonist; orally bioavailable

BQ-3020 (TFA) is a selective agonist of ETB receptor, inhibits [125I]ET-1 binding to ETB receptor with an IC50 of 0.2 nM in cerebellum, and causes vasoconstriction.

Nebentan free base (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan.

A-192621 is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM.

Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan.

C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP).

Ro 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist.

Endothelin 1 (swine, human) (TFA) is a synthetic peptide with human and porcine Endothelin 1 (ET-1) sequences and is a potent endogenous vasoconstrictor.